These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34885086)

  • 1. The Cost of Enfortumab Vedotin Wastage Due to Vial Size-A Real-World Analysis.
    Sarfaty M; Moore A; Regazzi AM; Mitchell AP; Rosenberg JE
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort.
    Zschäbitz S; Biernath N; Hilser T; Höllein A; Zengerling F; Cascucelli J; Paffenholz P; Seidl D; Lutz C; Schlack K; Kingreen D; Klümper N; Ivanyi P; von Amsberg G; Heers H; Roghmann F; Tauber RL; Cathomas R; Hofer L; Niegisch G; Klee M; Ehrenberg R; Hassler A; Hadaschik BA; Grünwald V; Darr C
    Eur Urol Open Sci; 2023 Jul; 53():31-37. PubMed ID: 37441344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A real-world analysis of cancer drug wastage due to oversized vials.
    Liran O; Prus J; Gordon N; Almog V; Gruenewald T; Goldstein DA
    J Am Pharm Assoc (2003); 2018; 58(6):643-646. PubMed ID: 30017368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
    Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ; Chiang R; Makrakis D; Talukder R; Lemke E; Olsen TA; Jain J; Jang A; Ali A; Jindal T; Chou J; Friedlander TW; Hoimes C; Basu A; Zakharia Y; Barata PC; Bilen MA; Emamekhoo H; Davis NB; Shah SA; Milowsky MI; Gupta S; Campbell MT; Grivas P; Sonpavde GP; Kilari D; Alva AS
    Cancer; 2022 Mar; 128(6):1194-1205. PubMed ID: 34882781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug wastage and costs to the healthcare system in the care of patients with non-small cell lung cancer in the United States.
    Hess LM; Cui ZL; Li XI; Oton AB; Shortenhaus S; Watson IA
    J Med Econ; 2018 Aug; 21(8):755-761. PubMed ID: 29673274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
    Powles T; Rosenberg JE; Sonpavde GP; Loriot Y; Durán I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Wu C; Campbell M; Matsangou M; Petrylak DP
    N Engl J Med; 2021 Mar; 384(12):1125-1135. PubMed ID: 33577729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world use, dose intensity, and adherence to enfortumab vedotin in locally advanced or metastatic urothelial cancer.
    Mamtani R; Tsingas K; Parikh RB; Elsouda D; Mucha L; Fuldeore R; Hubbard RA
    Urol Oncol; 2024 Jun; 42(6):177.e1-177.e4. PubMed ID: 38503592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
    Kawahara T; Hasizume A; Uemura K; Yamaguchi K; Ito H; Takeshima T; Hasumi H; Teranishi JI; Ousaka K; Makiyama K; Uemura H
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
    Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
    Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enfortumab Vedotin-related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature.
    Vlachou E; Matoso A; McConkey D; Jing Y; Johnson BA; Hahn NM; Hoffman-Censits J
    Eur Urol Open Sci; 2023 Mar; 49():100-103. PubMed ID: 36820243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study.
    Morikawa T; Naiki T; Sugiyama Y; Naiki-Ito A; Nagai T; Etani T; Iida K; Isobe T; Noda Y; Shimizu N; Aoki M; Gonda M; Banno R; Kubota H; Ando R; Umemoto Y; Kawai N; Yasui T
    Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin.
    Jain RK; Skelton WP; Zhang J
    Cancer Manag Res; 2020; 12():8379-8386. PubMed ID: 32982431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enfortumab Vedotin in urothelial cancer.
    Alt M; Stecca C; Tobin S; Jiang DM; Sridhar SS
    Ther Adv Urol; 2020; 12():1756287220980192. PubMed ID: 33447264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
    Halford Z; Anderson MK; Clark MD
    Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of Chemotherapy Drug Wastage and Incurred Financial Loss in Paediatric Cancer Care: A Cross-Sectional Study at a Tertiary Care Public Hospital in India.
    Ghate S; Patil S; Kadhe N; Fulsoundar R; Pawar S
    Cureus; 2024 Jan; 16(1):e52076. PubMed ID: 38344631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?
    Hoffman-Censits J; Lombardo K; McConkey D; Hahn NM; Bashir B; Kelly WK; Johnson B; Matoso A
    Urol Oncol; 2021 Oct; 39(10):619-622. PubMed ID: 34148797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First experience in treating advanced urothelial cancer with enfortumab vedotin. Single-centre retrospective study of patients qualified for a rescue access procedure.
    Sikora-Kupis B; Domański P; Fortuniak W; Kruczyk B; Staneta S; Piętak M; Mydlak A; Demkow T; Dumnicka P; Kucharz J
    Contemp Oncol (Pozn); 2023; 27(4):224-229. PubMed ID: 38405211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
    Minato A; Kimuro R; Ohno D; Tanigawa K; Kuretake K; Matsukawa T; Takaba T; Jojima K; Harada M; Higashijima K; Nagata Y; Tomisaki I; Harada K; Fujimoto N; Miyamoto H
    Anticancer Res; 2023 Sep; 43(9):4055-4060. PubMed ID: 37648337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal vial sizes for infliximab injection: a simulation study of Japanese demographic data.
    Nakamura N; Kusumoto M; Yano Y
    Int J Pharm Pract; 2021 Aug; 29(4):344-349. PubMed ID: 33881507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context.
    Hoffman-Censits J; Maldonado L
    Onco Targets Ther; 2022; 15():1519-1529. PubMed ID: 36545447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.